Eli Lilly hopes for cancer fame in Big Apple (Morning Read) MedCity News Wed, 29 Sep 2010 06:01 AM PDT Indianapolis drug maker Eli Lilly and Co. -- pushing to make a name for itself in cancer research after buying ImClone for $6.5 billion in 2008 -- has moved about 140 of its oncology researchers into a brand-new research center it is leasing in New York City, according to the Indianapolis Star. | Personal cost of cancer treatment tough financially, poll finds Canada.com Wed, 29 Sep 2010 05:49 AM PDT Most Canadians say that if they were diagnosed with cancer, the out-of-pocket cost of treating the disease would be a negative drain on their personal finances, with more than half calling it a "major" impact once the prices of newer drugs were factored in. | Singer to perform at charity event Hartlepool Mail Wed, 29 Sep 2010 05:46 AM PDT A TOP singer is set to perform at the first acoustic night for a new charity drive which aims to raise awareness and funds to tackle bowel cancer. | Coming Friday: The Power of Pink Palladium-Item Wed, 29 Sep 2010 05:40 AM PDT October is National Breast Cancer Awareness Month, a time to reflect on a disease that affects thousands of people in our community and across the nation. | Mersana Therapeutics has a new CEO Boston Globe Wed, 29 Sep 2010 05:36 AM PDT Mersana Therapeutics, a platform-based cancer therapeutics company, announced the appointment of Nicholas G. Bacopoulos as president and chief executive. Cancer - Chief executive officer - Business - Health - Conditions and Diseases | New program offers options for fertility preservation in children with cancer News-Medical-Net Wed, 29 Sep 2010 05:32 AM PDT It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship. | Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA PR Newswire via Yahoo! Finance Wed, 29 Sep 2010 05:30 AM PDT ACCESS PHARMACEUTICALS, INC. , a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies. Ã As a result of the continued advancements made with its Cobalamin ... | | |
|
No comments:
Post a Comment